An aspect of PAA I've long liked is the quality and depth of experience of the people in the company and that the MPL project has its roots in the work of the UNSW and now is being supported by the continuing work of the Olivia Newton John Cancer Research Centre. And let's not forget that the Epichem division, with its deep biochemistry talent and capacities is the perfect support for the Pitney division's drug development program, after all they've already synthesized a promising successor to MPL, though that's a long term project that's still very much in the lab stage.
Everything is coming together nicely. GLTAHs
Pharmaust Phase II K9 Trial, page-19
-
- There are more pages in this discussion • 541 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.015(6.25%) |
Mkt cap ! $109.4M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 22.5¢ | $133.9K | 573.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 303213 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 57592 | 2 |
View Market Depth
| Last trade - 15.46pm 18/10/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |